GlassScriptPhysician profile
Kaitlyn Gregory
NPI 1831648773
$1,980.73
in general payments reported to CMS, 2019-2025
9 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $359 · 2023: $22.22 · 2024: $182 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,364.26 | 2021-2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $249.40 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $152.14 | 2024-2025 | Keytruda, Lynparza |
| Masimo Corporation | $77.65 | 2022 | |
| Gilead Sciences, INC. | $55.64 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $25.16 | 2024 | Fruzaqla |
| Mirati Therapeutics, INC. | $22.22 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $17.86 | 2024 | Libtayo |
| Genmab U.S., INC. | $16.40 | 2024 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.